SAVA is tackling Rett and Parkinson’s as well?!? WOW, good to know! AVXL definitely has some competition there then! LOL If Anavex was in fact “riding anyone’s coattails” the share price would be much much higher. The fact of the matter is AVXL is not seen as a “hot/sexy” Alzheimer’s play at the moment so they are not reaping the benefits as a few others are. What have you done for me lately and what Wall St. firms are invested. Anavex is 0-2 under those Alzheimer’s pump regards. SAVA on the other hand is 2-2. The price is where it is solely due to the advancement of the other indications not just Alzheimer’s as there has been nothing flashy to report lately. If one wants to truly be unbiased check back after AAIC 2022 once Anavex has a fair shot in the fight and let’s see which company is far better off.
Lol. AVXL's pipeline is greatly undervalued; AVXL's MC will surpass SAVA's in less than 6 months... perhaps in 1-2 month, once the SAVA rug-pull happens.
You do realize why SAVA is trading at the astronomical prices that it is right? And no it’s not the science! LOL I’d look into the bonuses that will be received if it stays above $125 before I got too comfortable holding it long term!
News 
Market Data 
Discover 
